Consensus recommendations from an expert panel
Survival was significantly prolonged by combining standard ADT with enzalutamide than with a first-generation androgen-receptor.
Progression-free survival was significantly longer with fulvestrant plus alpelisib than with fulvestrant plus placebo.
Disease-free survival at 3 years was noninferior with laparoscopic versus open distal gastrectomy.
An Anticoagulation Forum guideline provides recommendations on the use of DOAC reversal agents.
The 5-year risk for recurrence was nearly 30% in men with unprovoked venous thromboembolism, despite negative D-dimer testing.
Progression-free survival and safety were better with this combination therapy than with standard sunitinib treatment.
Use of 5α-reductase inhibitors was associated with delayed diagnosis and worse mortality.
Specificity was high, but sensitivity was low; thus, autoantibody testing may rule in but not rule out ITP.
Relapsed or refractory patients had high response rates with anticipated, manageable toxicities.
Prof. Dr. med. Christoph Rochlitz
E-Mail: E-Mail anzeigen
In der vorliegenden Ausgabe von NEJM Journal Watch möchte ich Ihnen gerne wieder einige rezent publizierte Studien aus dem Bereich Onkologie/Hämatologie näherbringen.
Overall survival trended longer with the addition of palbociclib to endocrine therapy in patients with ER-positive/HER2-negative metastatic disease.
Adding atezolizumab to nab-paclitaxel prolonged progression-free survival in patients with metastatic triple-negative breast cancer.
Progression-free survival was prolonged with front-line brigatinib versus crizotinib.
Adding atezolizumab to chemotherapy significantly improved overall and progression-free survival.
Adding the PD-1 inhibitor pembrolizumab to carboplatin-taxane chemotherapy significantly improved response and survival.
Two-year overall survival was significantly improved with durvalumab versus placebo.
Long-term follow-up data confirm that axillary dissection is unnecessary in patients with minimal tumor burden in the sentinel nodes.
Progression-free survival was significantly longer with olaparib than with placebo.
Ipilimumab plus nivolumab proved safe and efficacious in a phase II trial.
Overall survival was noninferior and progression-free survival and response were superior with lenvatinib.